Reyon Pharmaceutical Co Ltd
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough … Read more
Reyon Pharmaceutical Co Ltd (102460) - Total Liabilities
Latest total liabilities as of September 2025: ₩239.99 Billion KRW
Based on the latest financial reports, Reyon Pharmaceutical Co Ltd (102460) has total liabilities worth ₩239.99 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Reyon Pharmaceutical Co Ltd - Total Liabilities Trend (2008–2024)
This chart illustrates how Reyon Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Reyon Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Reyon Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lay Hong Bhd
KLSE:9385
|
Malaysia | RM449.20 Million |
|
Aptech Limited
NSE:APTECHT
|
India | ₹1.74 Billion |
|
Dynacolor
TWO:5489
|
Taiwan | NT$478.89 Million |
|
Globus Maritime Ltd
NASDAQ:GLBS
|
USA | $116.02 Million |
|
FASOO.COM Co Ltd
KQ:150900
|
Korea | ₩12.12 Billion |
|
Damsan JSC
VN:ADS
|
Vietnam | ₫1.49 Trillion |
Liability Composition Analysis (2008–2024)
This chart breaks down Reyon Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Reyon Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Reyon Pharmaceutical Co Ltd (2008–2024)
The table below shows the annual total liabilities of Reyon Pharmaceutical Co Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩250.05 Billion | -0.44% |
| 2023-12-31 | ₩251.15 Billion | +6.00% |
| 2022-12-31 | ₩236.93 Billion | +1.80% |
| 2021-12-31 | ₩232.74 Billion | +165.93% |
| 2020-12-31 | ₩87.52 Billion | +67.69% |
| 2019-12-31 | ₩52.19 Billion | -32.90% |
| 2018-12-31 | ₩77.77 Billion | +9.27% |
| 2017-12-31 | ₩71.18 Billion | +133.83% |
| 2016-12-31 | ₩30.44 Billion | -0.42% |
| 2012-12-31 | ₩30.57 Billion | +6.39% |
| 2011-12-31 | ₩28.73 Billion | +29.70% |
| 2009-12-31 | ₩22.15 Billion | -2.14% |
| 2008-12-31 | ₩22.64 Billion | -- |